84-patient study tests oral drug for lung disease with no approved therapies Patient screening is underway at an estimated 10-15 U.S. sites. Why it matters: current care relies on prolonged daily IV regimens; data are due late 2027.

#ANTX AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

www.stocktitan.net/news/ANTX/an2-therapeuti...

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2025.. “Our recent decision to advance oral epetraborole into a Phase 2 study for...

#ANTX AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

www.stocktitan.net/news/ANTX/an2-therapeuti...

AN2 Therapeutics Announces $40 Million Private Placement Financing AN2 Therapeutics (Nasdaq: ANTX) entered a securities purchase agreement for a private placement expected to raise approximately $40 million gross, before placement agent fees and expenses. The company will sell 8,245,611 common shares at $2.85 each and offer pre-funded warrants for up to 5,789,493 shares at $2.84999 each.The pre-funded warrants carry a $0.00001 exercise price and are exercisable immediately subject to ownership limits. The offering is expected to close on March 10, 2026, subject to customary conditions, and AN2 will file a registration statement to register resale of the securities.

#ANTX AN2 Therapeutics Announces $40 Million Private Placement Financing

www.stocktitan.net/news/ANTX/an2-therapeuti...

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera.

#ANTX AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

www.stocktitan.net/news/ANTX/an2-therapeuti...

#ANTX AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

www.stocktitan.net/news/ANTX/an2-therapeuti...

#ANTX AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

www.stocktitan.net/news/ANTX/an2-therapeuti...

AN2 Therapeutics Secures Runway Through 2028, Makes Progress in Chagas Disease Treatment Biotech firm reports $71.2M cash position and pipeline advances in Chagas disease, melioidosis, and oncology programs. Phase 1 dosing begins for oral treatment. See full details.

#ANTX AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

www.stocktitan.net/news/ANTX/an2-therapeuti...

First Potential Oral Cure for Chagas Disease Enters Human Trials, Targets 7M Patient Market Phase 1 trial begins for AN2-502998, showing promise as first FDA-approved Chagas disease treatment. Preclinical success signals breakthrough potential. See timeline.

#ANTX AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

www.stocktitan.net/news/ANTX/an2-therapeuti...

New Oral Treatment Could Transform Chagas Disease Care for 7 Million Patients Worldwide AN2 Therapeutics partners with DNDi to advance novel oral treatment for Chagas disease, targeting 7M patients globally. Phase 1 trials starting now. See development timeline.

#ANTX AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

www.stocktitan.net/news/ANTX/an2-therapeuti...

NIH-Backed Study Reveals Alarming 40% Death Rate in Melioidosis: AN2 Therapeutics Advances Biodefense Drug NIH-funded study of 200 patients reveals critical mortality data for biothreat infection. AN2 Therapeutics advances epetraborole treatment toward Phase 2 trial. See findings.

#ANTX AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

www.stocktitan.net/news/ANTX/an2-therapeuti...

New Drug Could Fight Fatal Lung Disease With 45% Mortality Rate: Key Data Revealed Latest preclinical data reveals epetraborole's potential against M. abscessus affecting 50,000 patients. See breakthrough findings for this deadly infection. Get insights.

#ANTX AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

www.stocktitan.net/news/ANTX/an2-therapeuti...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping down in trading, Wed May 28th - #SYNX #OGEN #REVB #ELPW #BSLK #SAMG #PLAB #IFRX #CXDO #ANTX #VATE #GWH #CBAN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

AN2 Therapeutics Earnings Reveal $1B Market Opportunity and Extended Cash Runway Through 2028 AN2 reports strong Q1 financials with $78.5M cash position and advances multiple drug candidates. Pipeline includes potential $1B Chagas treatment. See full details.

#ANTX AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

www.stocktitan.net/news/ANTX/an2-therapeuti...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Tue May 6th - #TRUE #SEAT #REPL #PRAA #OFIX #GDRX #CAPR #FWRG #ANTX #SQNS #PACK #HZAC #ETD #BRCC - More: crystalequityresearch.com/SmCpStr/ - #smallcap

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline AN2 Therapeutics (NASDAQ: ANTX) reported that its Phase 3 EBO-301 study for epetraborole in MAC lung disease failed to meet its primary endpoint. Despite this setback, the company is pivoting focus to its broader boron chemistry pipeline. Key developments include: Pipeline Updates: - Initiated Phase 1 study of AN2-502998 for Chagas disease, with estimated $1B peak sales potential - Planning Phase 2 study for epetraborole in melioidosis in 2H25 - Pursuing M. abscessus lung disease treatment through non-dilutive funding - First oncology compounds targeting ENPP1 and PI3Kα expected to enter development in 2H25 Financial Position: - $78.5M cash position as of March 31, 2025 - Extended cash runway into 2028 - Implemented strategic workforce reduction and operational optimization

#ANTX AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

www.stocktitan.net/news/ANTX/an2-therapeuti...

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics (ANTX) reported its Q4 and full year 2024 financial results, highlighting key pipeline developments. The company expects Phase 3 topline data for epetraborole in treatment-refractory MAC lung disease in Q2 2025. A Phase 1 study for AN2-502998 in Chagas disease is planned for mid-2025, while melioidosis trial data is expected in Q2 2025.Financial highlights include cash position of $88.6 million as of December 31, 2024, expected to fund operations through 2027. Full-year 2024 R&D expenses were $40.5 million, down from $54.9 million in 2023. The company reported a net loss of $51.3 million for 2024, improved from $64.7 million in 2023.The company amended its statistical analysis plan, selecting QOL-B respiratory domain as the primary efficacy endpoint for the Phase 3 epetraborole trial. Additionally, ANTX is advancing its boron chemistry platform with first oncology candidates expected in 2H25.

#ANTX AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

www.stocktitan.net/news/ANTX/an2-therapeuti...

Can AN2's Strategic Pivot Save Its MAC Lung Disease Treatment? Phase 2 Data Offers Hope AN2 selects QOL-B respiratory endpoint for Phase 3 MAC lung trial following promising Phase 2 results. FDA decision expected Q2 2025.

#ANTX AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

www.stocktitan.net/news/ANTX/an2-provides-s...

Well, pretty much everyone now has a family to feed. #AntX?

#ANTX AN2 Therapeutics to Participate at Upcoming Investor Conferences

www.stocktitan.net/news/ANTX/an2-therapeuti...

#ANTX AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

www.stocktitan.net/news/ANTX/an2-therapeuti...